Back to companies

Alphamab Oncology (Alphamab) is a clinical-stage biopharmaceutical company.

Headquarters China

Address No. 175, Fangzhou Road, Suzhou Industrial Park, Jiangsu, 215125


Telephone 86 512 62850800

No of Employees 459

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange 9966 (HKG)

Revenue (2020) $22.6M

EPS XXX

Net Income (2020) XXX 3.6% (2020 vs 2019)

Market Cap* $784.1M

Net Profit Margin (2020) XXX 0.0% (2020 vs 2019)

* As of and is in US$

Access premium data and analytics for Alphamab Oncology

90+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Alphamab Oncology’s relevant decision makers and contact details.

90+

Catalyst Calendar

Proactively evaluate Alphamab Oncology’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

60+

Clinical Trials

Determine Alphamab Oncology go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

50+

Pipeline Drugs

Identify which of Alphamab Oncology’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

3

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Pipeline Products
KN035
KN046
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Official Trials/Tests In June, the company announced that the first patient was dosed in a Phase I clinical study (KN052-CHN-001) of KN052.
2022 Official Trials/Tests In May, the company announced the first patient successfully dosed in a phase II clinical trial of KN026 (KN026-205).
2022 Regulatory Approval In February, the company received the IND approval from the National Medical Products Administration (NMPA) for the company's innovative bispecific antibody KN052.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Alphamab Oncology CStone Pharmaceuticals Co Ltd Antengene Corp Ltd Adagene Suzhou Ltd Ascepion Pharmaceuticals Inc
Headquarters China China China China China
City Suzhou Shanghai Shanghai Suzhou Suzhou
State/Province Jiangsu Shanghai Shanghai Jiangsu Jiangsu
No. of Employees 459 263 329 - -
Entity Type Public Public Public Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Ting Xu, Ph.D. Chairman; Chief Executive Officer; Director; Founder Executive Board 2008 -
Yang Liu Director; Vice President - Corporate Operations Executive Board 2018 50
Wang Jin’nan Secretary Senior Management 2020 39
Chan Lok Yee Secretary Senior Management 2020 -
Zijian Guo Director Non Executive Board 2021 60
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer